Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Viridian Therapeutics, Inc.

A Decade of SG&A: Insmed vs. Viridian

In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, Insmed Incorporated and Viridian Therapeutics, Inc. have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. Insmed's SG&A costs have surged by over 1,000% from 2014 to 2023, reflecting its aggressive expansion and strategic investments. In contrast, Viridian's expenses, while increasing, have remained relatively modest, growing by approximately 1,200% during the same period.

Key Insights

• Insmed's Growth: By 2023, Insmed's SG&A expenses reached nearly 10 times that of 2014, indicating a robust growth strategy.
• Viridian's Strategy: Despite a significant increase, Viridian's expenses are still less than a third of Insmed's, suggesting a more conservative approach.
  This analysis underscores the diverse strategies within the biotech sector, where companies balance growth with operational costs.